Rua Bioscience Full Year 2024 Earnings: NZ$0.087 loss per share (vs NZ$0.039 loss in FY 2023)

Rua Bioscience (NZSE:RUA) Full Year 2024 Results

Key Financial Results

• Net loss: NZ$13.7m (loss widened by 130% from FY 2023).
• NZ$0.087 loss per share (further deteriorated from NZ$0.039 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

In the last 12 months, the only revenue segment was Research and Development and The Sale of Pharmaceutical Products contributing NZ$316.4k. Notably, cost of sales worth NZ$204.1k amounted to 65% of total revenue thereby underscoring the impact on earnings. The most substantial expense, totaling NZ$9.10m were related to Non-Operating costs. This indicates that a significant portion of the company's costs is related to non-core activities. Explore how RUA's revenue and expenses shape its earnings.

Rua Bioscience shares are up 14% from a week ago.

Risk Analysis

Before you take the next step you should know about the 5 warning signs for Rua Bioscience that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.